Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CAPITROL vs 8-HOUR BAYER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ciclopirox is a hydroxypyridine antifungal agent that inhibits the uptake of essential elements and amino acids, disrupts fungal cell membrane integrity, and chelates polyvalent cations (e.g., Fe3+, Al3+), inhibiting metal-dependent enzymes such as cytochromes and catalase.
Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Topical treatment of seborrheic dermatitis of the scalp in adults
Relief of pain, fever, and inflammation,Reduction of risk of myocardial infarction in patients with previous MI or unstable angina,Prevention of recurrent ischemic stroke or transient ischemic attack
Apply 1 m L of 1% shampoo twice weekly for 4 weeks, then weekly for maintenance. Use on wet hair, lather for 2-3 minutes, rinse thoroughly.
325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.
Terminal elimination half-life is 20-40 hours; clinically, steady-state is achieved within 5-7 days.
15-20 hours (terminal elimination half-life) for salicylate at therapeutic concentrations; prolonged to 20-30 hours at high doses due to saturation of hepatic metabolism (zero-order kinetics).
Ciclopirox is primarily metabolized via glucuronidation, with less than 2% excreted unchanged in urine. The major metabolite is ciclopirox glucuronide.
Hepatic hydrolysis by esterases to salicylic acid, which is primarily conjugated in the liver via glucuronidation and glycine conjugation (salicyluric acid), with minor oxidation by cytochrome P450 (CYP2C9) to gentisic acid.
Primarily renal (approximately 60-70% as unchanged drug); biliary/fecal elimination accounts for about 20-30%.
Renal excretion of conjugated salicylate metabolites (75% as salicyluric acid, 10% as salicyl phenolic glucuronide, 5% as salicyl acyl glucuronide, 5% as gentisic acid); 10% free salicylate; approximately 10% eliminated in feces via bile.
>99% bound to albumin and alpha-1-acid glycoprotein.
80-90% bound to albumin; binding is concentration-dependent and saturable.
0.3 L/kg; indicates distribution primarily into extracellular fluid.
0.15-0.2 L/kg for salicylate; distributes into synovial fluid, CNS, and placental tissues; Vd increases in acidosis.
Oral: 70-80%; Topical: approximately 5-10%.
Oral: Approximately 100% for immediate-release, but extended-release may have slightly reduced absorption (relative bioavailability 85-90% compared to immediate-release).
No adjustment required as systemic absorption is negligible.
Avoid in severe renal impairment (Cr Cl <30 m L/min). Use with caution and monitor for bleeding in moderate impairment. Reduce dose or extend interval.
No adjustment required as systemic absorption is negligible.
Avoid in severe hepatic impairment. Use with caution in moderate impairment; monitor liver function.
Safety and efficacy not established in children under 12 years; use same as adult for ages 12 and above.
Not recommended in children <12 years for viral infections due to Reye's syndrome risk (contraindicated).
No specific dose adjustment; caution with dry or aged skin due to potential irritation.
Increased risk of GI bleeding and renal impairment; use lowest effective dose, monitor renal function and signs of bleeding.
None.
None
Avoid contact with eyes,If irritation or sensitization occurs, discontinue use,Not for oral, ophthalmic, or intravaginal use
Increased risk of gastrointestinal bleeding and ulceration; Reye syndrome in children with viral illness; Hemorrhagic stroke risk with high doses; Impaired renal function in predisposed patients; Bronchospasm in aspirin-sensitive asthma; Anaphylactic reactions; Use caution in patients with hepatic impairment or G6PD deficiency.
Hypersensitivity to ciclopirox or any component of the formulation
Known hypersensitivity to NSAIDs or aspirin; Active peptic ulcer disease or GI bleeding; Severe renal impairment (e GFR <30 m L/min); Hemorrhagic diathesis; Children with viral infection (Reye syndrome); Third trimester of pregnancy; Severe hepatic impairment.
No known food interactions when applied topically. However, avoid applying immediately before consuming food to minimize accidental ingestion.
Avoid alcohol; may increase risk of gastrointestinal bleeding. No specific food restrictions, but taking with food can reduce gastric irritation. Avoid high-dose vitamin C supplements as they may increase salicylate levels.
No adequate human studies; animal studies not available. Only minimal systemic absorption occurs with topical scalp application; theoretical risk low. First trimester: unlikely to cause harm due to negligible absorption; however, avoid elective use. Second and third trimesters: no known risks.
First trimester: No well-controlled studies. Avoid use unless clearly needed. Second and third trimesters: Aspirin should be avoided due to risk of premature closure of ductus arteriosus, oligohydramnios, and increased risk of maternal and fetal bleeding. High doses may cause constriction of ductus arteriosus in utero and persistent pulmonary hypertension in newborn.
Minimal systemic absorption; expected to be safe during breastfeeding. M/P ratio not determined. Avoid application to breast area.
Small amounts of aspirin are excreted in breast milk. M/P ratio not established. Use with caution in breastfeeding women; avoid high doses due to risk of Reye's syndrome in infants and potential for adverse effects on platelet function.
No dose adjustment required; topical use only.
Pregnancy increases clearance of aspirin; however, dose adjustments are not routinely recommended due to narrow therapeutic index. Use lowest effective dose for shortest duration. Avoid in third trimester.
Capitrol (chloroxine) is a topical antibacterial shampoo indicated for dandruff and seborrheic dermatitis. It is generally used twice weekly for 2 weeks, then as needed. Avoid contact with eyes and mucous membranes. Discontinue if local irritation or allergic reaction occurs.
8-Hour Bayer is enteric-coated aspirin designed for extended release, reducing gastrointestinal irritation. Onset of action is delayed; not suitable for acute pain or rapid antiplatelet effect. Use with caution in patients with history of peptic ulcer disease or on anticoagulants. Monitor renal function in elderly or dehydrated patients. Avoid in children with viral illness due to Reye's syndrome risk.
Use exactly as directed; do not use more often than prescribed.,Wet hair and scalp thoroughly before applying shampoo.,Massage into scalp and leave on for 2-3 minutes before rinsing.,Avoid contact with eyes; if occurs, rinse thoroughly with water.,Use caution to avoid staining of clothing or jewelry; rinse shampoo off completely.,Consult healthcare provider if condition persists or worsens after 2 weeks.,Inform doctor if you are pregnant, planning to become pregnant, or breastfeeding.
Take with a full glass of water; do not crush or chew the tablet.,Do not use within 7 days before surgery due to bleeding risk.,If used for pain, consult a doctor if symptoms persist for more than 10 days.,Avoid alcohol while taking this medication to reduce stomach bleeding risk.,Seek medical attention for signs of bleeding (black stools, blood in vomit).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CAPITROL vs 8-HOUR BAYER, answered by our medical review team.
CAPITROL is a Topical Antimicrobial that works by Ciclopirox is a hydroxypyridine antifungal agent that inhibits the uptake of essential elements and amino acids, disrupts fungal cell membrane integrity, and chelates polyvalent cations (e.g., Fe3+, Al3+), inhibiting metal-dependent enzymes such as cytochromes and catalase.. 8-HOUR BAYER is a NSAID that works by Irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting prostaglandin and thromboxane A2 synthesis, leading to analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CAPITROL and 8-HOUR BAYER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CAPITROL is: Apply 1 m L of 1% shampoo twice weekly for 4 weeks, then weekly for maintenance. Use on wet hair, lather for 2-3 minutes, rinse thoroughly.. The standard adult dose of 8-HOUR BAYER is: 325-650 mg every 8 hours for pain/fever; 81-325 mg daily for cardiovascular prophylaxis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CAPITROL and 8-HOUR BAYER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CAPITROL is classified as Category C. No adequate human studies; animal studies not available. Only minimal systemic absorption occurs with topical scalp application; theoretical risk low. First trimester: unlikely to . 8-HOUR BAYER is classified as Category C. First trimester: No well-controlled studies. Avoid use unless clearly needed. Second and third trimesters: Aspirin should be avoided due to risk of premature closure of ductus arte. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.